Table 2.
Demographics and clinical parameters of the study population
| Parameters | Mild | Severe |
|---|---|---|
| Subjects enrolled | n = 30 | n = 15 |
| Median age (range) | 39 (18–81) | 48 (22–70) |
| Gender (M/F) | 14/16 | 12/3 |
| Fever, no. (%) | 17 (57) | 13 (87) |
| Chills, no. (%) | 4 (13) | 6 (40) |
| Cough, no. (%) | 15 (50) | 7 (47) |
| Sore throat, no. (%) | 16 (53) | 5 (33) |
| Runny nose, no. (%) | 5 (17) | 2 (13) |
| Taste loss, no. (%) | 21 (70) | 5 (33) |
| Smell loss, no. (%) | 17 (57) | 6 (40) |
| Muscle aches, no. (%) | 24 (80) | 9 (60) |
| Joint pain, no. (%) | 18 (60) | 5 (33) |
| Abdominal pain, no. (%) | 2 (7) | 1 (7) |
| Vomit, no. (%) | 2 (7) | 1 (7) |
| Diarrhea, no. (%) | 4 (13) | 6 (40) |
| Seizures, no. (%) | NIL | NIL |
| Hypertension, no. (%) | 7 (23) | 5 (33) |
| Diabetes, no. (%) | 4 (13) | 4 (27) |
| Asthma, no. (%) | 1 (3) | 1 (7) |
| Chronic kidney disease, no. (%) | NIL | NIL |
| Neuro, no. (%) | NIL | NIL |
| Heart, no. (%) | NIL | 1 (7) |
| Rheumatic fever, no. (%) | NIL | NIL |
| Corticosteroids, no. (%) | NIL | 3 (20) |
| Antiviral drug, no. (%) | NIL | 4 (27) |
| Required hospitalization no. (%) | NIL | 6 (40) |
| Required mechanical oxygen support no. (%) | NIL | NIL |